Evaluation of miRNA-126 Expression and Some Immunological Parameters as Diagnostic Biomarker in Chronic Myeloid Leukemia Iraqi Patients

Abstract

Chronic Myeloid Leukemia (CML) is a hematologic malignancy characterized by the uncontrolled proliferation of myeloid cells in the bone marrow. Recent advancements in cancer research have highlighted the crucial role of cancer stem cells (CSCs) in tumor initiation, progression, and treatment resistance. The aim of this research is to investigate the potential of miRNA-126, CD33, and TNF-alpha as biomarkers for identifying and characterizing CSCs in a cohort of Iraqi patients with CML.The research methodology involves the collection of bone marrow samples from a cohort of Iraqi CML patients. Subsequently, various molecular techniques, including polymerase chain reaction (PCR) and flow cytometry, are employed to analyze the expression levels of miRNA-126 and CD33, in these samples. The choice of these biomarkers is based on their known associations with cancer stem cells and their relevance to CML.The results of this study showed that there were significant increases in miRNA-126 and  CD33 (p<0.05) in a sample of Iraqi patients with CML compared to healthy people. It was concluded the dramatic increases in the expression of each parameter as shared above.